Rocket Pharmaceuticals, Inc. (RCKT): Price and Financial Metrics
GET POWR RATINGS... FREE!
RCKT Stock Price Chart Interactive Chart >
RCKT Price/Volume Stats
| Current price | $11.56 | 52-week high | $49.66 |
| Prev. close | $10.24 | 52-week low | $7.57 |
| Day low | $9.87 | Volume | 874,300 |
| Day high | $11.60 | Avg. volume | 587,371 |
| 50-day MA | $12.52 | Dividend yield | N/A |
| 200-day MA | $21.94 | Market Cap | 761.09M |
Rocket Pharmaceuticals, Inc. (RCKT) Company Bio
Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
Latest RCKT News From Around the Web
Below are the latest news stories about Rocket Pharmaceuticals Inc that investors may wish to consider to help them evaluate RCKT as an investment opportunity.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational ResultsCRANBURY, N.J., February 24, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, 2021. |
Hedge Fund and Insider Trading News: Leon Cooperman, Graticule Asset Management, Blackwells Capital, AQR Capital Management, Maverick Capital, Bridgewater Associates, Rocket Pharmaceuticals Inc (RCKT), and MoreFrom Citizen Kane, chairman of the board Bernstein quips, its no trick to make a lot of money if what you want to do is make a lot of money. Downright laughable was Washington Posts catchy |
Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare ConferenceCRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET. A live audio webcast of the presentation will be available under Events in the Investors sect |
Insider Buying: The Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CEO & Director Just Bought 2.4% More SharesPotential Rocket Pharmaceuticals, Inc. ( NASDAQ:RCKT ) shareholders may wish to note that the CEO & Director, Gaurav... |
Strong Insider Buying Could Indicate a Bottom in These 2 StocksWe saw large market declines as 2022 got started – but the real story was the increase in volatility. Especially at the beginning of February, when the market losses leveled off, daily trading was characterized by strong swings up and down. It’s a situation that puts a burden on investors, to recognize the right time to buy in for optimal profits. The key is not to try and ‘time’ it on daily trading, but to look at longer trends and future predictors. One place to find indicators toward a stock’ |
RCKT Price Returns
| 1-mo | 9.47% |
| 3-mo | -35.24% |
| 6-mo | -51.00% |
| 1-year | -72.80% |
| 3-year | -32.63% |
| 5-year | 65.14% |
| YTD | -47.05% |
| 2021 | -60.19% |
| 2020 | 140.95% |
| 2019 | 53.58% |
| 2018 | 41.95% |
| 2017 | -57.21% |
Loading social stream, please wait...